Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirtazapine versus ondansetron for prevention of radiotherapy-induced nausea and vomiting in patients with brain tumors
IRCT20251001067447N1Phase 3Completed
- Sponsor
- Shahid Sadoughi University of Medical Sciences
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in post-radiation nausea and vomiting (RINV) comparing Mirtazapine with Ondansetron control (2 arms). Primary endpoints: Complete control in acute phase, Complete control in delayed phase and 5 more. Started Oct 2025; status: completed.
02
Drugs
mirtazapineondansetron
03
Conditions
post-radiation nausea and vomiting (RINV)
Beyond the preview
Go deeper on IRCT20251001067447N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251001067447N1.